News and Trends 15 Oct 2024 Booster launches to treat neurodegenerative diseases with proteasome activation Discover Booster Therapeutics’ novel proteasome activation approach to neurodegenerative diseases as it launches with $15 million. October 15, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Expert Advice 11 Oct 2024 How to build your biotech company in 2024 (according to founders) Discover the insight successful biotech founders share with us to build your biotech company – from building your team to attracting funding. October 11, 2024 - 19 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2024 Spinal cord injury: Are we getting closer to a treatment? Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition. October 7, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2024 Resolution Therapeutics raises $85 million to advance its macrophage therapy Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round. October 3, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Oct 2024 Lithuania’s biotech: Six companies to put on your radar Here are six companies at the forefront of Lithuania’s growing biotech scene, showcasing innovations in protein engineering and gene editing. October 1, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 27 Sep 2024Harnessing the body’s natural targeted protein degradation system to treat diseases Listen to our conversation with Andrew Hirsch, CEO at C4 Therapeutics, a leader in the targeted protein degradation field. September 27, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 26 Sep 2024 The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving innovation. September 26, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2024 Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses Discover Vicebio’s molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against RSV and hMPV. September 23, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Sep 2024 Estonia: Seven biotech companies to reckon with Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks and universities. September 17, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2024 Vironexis’ AAV vector approach: The next frontier in cancer immunology? Delve into Vironexis’ launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform. September 16, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 13 Sep 2024Targeting inflammation: A revolution in disease treatment NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies. Listen to our conversation with Halia Therapeutics about it. September 13, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 12 Sep 2024 Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges Delve into the consequences of the Inflation Reduction Act and the broader economic conditions on biotech R&D. September 12, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email